Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Part of paid clinical trials in New York, New York.

Sponsor
Yaakov Stern
Study ID
NCT03372317
Status
Recruiting

Conditions

  • Aging
  • Mild Cognitive Impairment

Eligibility Criteria

Sex
ALL
Age
55 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • 18F-MK-6240 — DRUG
    Results of the 18F-MK-6240 PET scan will be correlated with other observations.

Study Details

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

Key Dates

Start date
Jun 1, 2018
Status verified
Feb 2026
Primary completion
Jan 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
105 participants (estimated)

Arms

  • Arm: Non-demented elders
    Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.

Primary Outcome Measure

Total number of individuals with tau present [ Time Frame: Up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbia University Medical CenterNew YorkNew York10032
Ashley Mensing, BS
212-305-6314
Yaakov Stern, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

Related Studies